Key result
The presence and extent of late gadolinium enhancement (>4.5%) on cardiac MRI significantly predicted major adverse cardiac events in patients with dilated (p=0.007) and hypertrophic (p=0.014) cardiomyopathies.
Why the study?
To investigate cardiac MR imaging data, tissue characterization, and fibrosis assessment by LGE, along with their prognostic value in non-ischemic cardiomyopathies.
Cohort (n=46)
Answers are grounded in this paper and cite their sources.
The presence and extent of late gadolinium enhancement (LGE > 4.5%) on cardiac MRI is a significant predictor of major adverse cardiac events in patients with non-ischemic cardiomyopathies.
Background: Cardiac MR (CMR) evaluatingnon-ischemic cardiomyopathies (NICMs) is superior 3D imaging with non-invasiveness, more accuracy and reproducibility of measurements. It provides comprehensive structural, functional information, tissue characterization, and assesses fibrosis by LGE. Objective: The study aimed to investigate these imaging data and their prognostic value in NICM. Patients and methods: 46 NICM patients were assessed by echocardiography/cardiac magnetic resonance (CMR). They were divided into 3 groups: dilated, hypertrophic and miscellaneous types. Late gadolinium enhancement (LGE) presence and myocardial extent/percentage were assessed with clinical follow up for a median of 1-year for any Major adverse cardiac events (MACE). For each group, univariate analysis of clinical/imaging risk factors in the associations with LGE/MACE was performed. Results: Twenty-six dilated cardiomyopathypatients, 62% had LGE and 31% had MACE. Using LGE as a predictor for MACE was statistically significant (p = 0.007). Using univariate analysis, the presence of LGE (p=0.00) and the extent of LGE (p < 0.0001) demonstrated the strongest unadjusted association with MACE. ROC curves revealed a cutoff value of LGE > 4.5% as MACE predictor. Twelve hypertrophic cardiomyopathypatients (67%) had LGE and (50%) had MACE. Using LGE as a predictor for MACE was statistically significant (p=0.014). Using univariate analysis, the presence of LGE (p=0.01) and the extent of LGE (p=0.01) demonstrated the strongest unadjusted association with MACE. ROC curves revealed a cutoff value of LGE > 4.5% as MACE predictor. Conclusion: CMR with LGE is crucial in NICM evaluation with prognostic value; changing the way that myocardial disorders will be understood and managed in the near future.
No takes yet. Share an insight, caveat, or question.
Sameeh et al. (2022) conducted a cohort in Non-ischemic cardiomyopathies (n=46). Late gadolinium enhancement (LGE) on cardiac MRI vs. Absence of LGE or LGE ≤ 4.5% was evaluated on Major adverse cardiac events (MACE). The presence and extent of late gadolinium enhancement (>4.5%) on cardiac MRI significantly predicted major adverse cardiac events in patients with dilated (p=0.007) and hypertrophic (p=0.014) cardiomyopathies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: